BetterLife Pharma Inc.
BETR
CNSX
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 141.91% | 26.73% | -48.70% | -570.47% | 81.17% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -287.36% | -80.68% | 176.94% | 242.80% | -269.36% |
| Change in Net Operating Assets | -230.55% | 126.86% | -199.89% | 145.80% | -39.77% |
| Cash from Operations | 85.78% | -15.55% | -234.92% | 35.16% | 16.64% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -100.00% | 308.07% | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.12% | -- | -- | -- | 52.64% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -- | -- | -- |
| Cash from Financing | -95.11% | -43.86% | 519.24% | -52.94% | 49.93% |
| Foreign Exchange rate Adjustments | -- | -- | 100.00% | -200.00% | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 63.62% | -176.24% | 794.62% | -275.54% | 116.67% |
